{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:16:55Z","timestamp":1790543815375,"version":"4.1.0"},"reference-count":21,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"4","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi Turkey"},{"name":"Sanofi Turkey"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AOTT"],"abstract":"<jats:p>Objective: In our study, we aimed to evaluate the influence of training on compliance and persistence with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis patients.\n\nMethods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 \u00b1 7.2 years) were included in this national, multicenter, prospective non-interventional observational cohort registry study. Patients were randomized into training (n &amp;frac14; 492, 50.3%, mean age: 63.4 \u00b1 7.2 years) and control (n &amp;frac14; 487, 49.7%, mean age: 63.0 \u00b1 7.1 years) groups. Patients in each intervention group were given weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%, respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse events.\n\nResults: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days of duration during the 12-month follow-up period. The mean compliance in the compliant and fully compliant group remained at an average of 86.6%. No significant difference was detected between the training and control groups in terms of compliance and persistence. Significantly longer persistence (360.0 \u00b1 89.0 vs. 345.0 \u00b1 108.0 days; p &amp;frac14; 0.035), higher percentage of persistent patients (83.4% vs. 74.2%; p &amp;frac14; 0.012) and higher compliance rates (88.8% vs. 83.3%; p &amp;frac14; 0.002) were noted in monthly regimen patients in comparison to those given weekly regimen.\n\nConclusion: Our findings revealed remarkably high rates for persistence and compliance with bisphosphonate treatment in postmenopausal osteoporosis, with no impact of training on compliance and persistence rates. Longer persistence and better compliance rates were achieved with the monthly bisphosphonate regimen when compared to the weekly regimen.<\/jats:p>","DOI":"10.1016\/j.aott.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T18:06:40Z","timestamp":1471025200000},"page":"415-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis"],"prefix":"10.5152","volume":"50","author":[{"given":"Ulku","family":"Akarirmak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmet","family":"Kocyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurten","family":"Eskiyurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Esmaeilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Yalcinkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlen","family":"Peker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Ekim Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese","family":"Ozgirgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Calis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"Celikol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Eyigor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Faruk Sendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jale","family":"\u0130rdesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"10.1016\/j.aott.2016.07.001_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.clinthera.2006.10.013","article-title":"The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France","volume":"28","author":"Cramer","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.aott.2016.07.001_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/11203300-000000000-00000","article-title":"Denosumab: a review of its use in the treatment of postmenopausal osteoporosis","volume":"28","author":"Moen","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.aott.2016.07.001_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/ciia.2006.1.4.415","article-title":"Patient preference in the management of postmenopausal osteoporosis with bisphosphonates","volume":"1","author":"Reginster","year":"2006","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.aott.2016.07.001_bib4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jval.2012.02.001","article-title":"The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland","volume":"15","author":"Hiligsmann","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.aott.2016.07.001_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(06)69394-X","article-title":"Compliance with osteoporosis therapy is the weakest link","volume":"368","author":"Compston","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.aott.2016.07.001_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jbspin.2006.02.006","article-title":"Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis?","volume":"73","author":"Cortet","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.aott.2016.07.001_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.maturitas.2008.07.009","article-title":"Self-reported compliance with osteoporosis medication-qualitative aspects and correlates","volume":"60","author":"Vytrisalova","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.aott.2016.07.001_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.drudis.2013.08.010","article-title":"Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?","volume":"19","author":"Verron","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.aott.2016.07.001_bib9","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.clinthera.2008.12.019","article-title":"Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis","volume":"30","author":"Cott\u00e9","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.aott.2016.07.001_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A\u00a0systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.aott.2016.07.001_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","article-title":"Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis","volume":"28","author":"Penning-van Beest","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.aott.2016.07.001_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","article-title":"Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study","volume":"60","author":"Cooper","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.aott.2016.07.001_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pec.2009.12.012","article-title":"Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital","volume":"81","author":"Jans\u00e0","year":"2010","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.aott.2016.07.001_bib14","first-page":"417","article-title":"Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial","volume":"15","author":"Shu","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.aott.2016.07.001_bib15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00198-005-0031-8","article-title":"OPTIMA study investigators. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study","volume":"17","author":"Guilera","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.aott.2016.07.001_bib16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A\u00a0systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.aott.2016.07.001_bib17","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.aott.2016.07.001_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0272989X08318461","article-title":"Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis","volume":"29","author":"Cott\u00e9","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.aott.2016.07.001_bib19","first-page":"209","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am J Meat"},{"key":"10.1016\/j.aott.2016.07.001_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.aott.2016.07.001_bib21","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0378-5122(09)70092-1","article-title":"Persistence and compliance with antiresorptive treatment for osteoporosis: the Israeli experience","volume":"63","author":"Nahum","year":"2009","journal-title":"Maturitas"}],"container-title":["Acta Orthopaedica et Traumatologica Turcica"],"original-title":[],"link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1017995X16300141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1017995X16300141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aott.org.tr\/index.php\/pub\/article\/download\/3150\/3102","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:02:33Z","timestamp":1763463753000},"score":1,"resource":{"primary":{"URL":"https:\/\/aott.org.tr\/index.php\/pub\/article\/view\/3150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,1,4]]}},"URL":"https:\/\/doi.org\/10.1016\/j.aott.2016.07.001","relation":{},"ISSN":["2589-1294","1017-995X"],"issn-type":[{"value":"2589-1294","type":"electronic"},{"value":"1017-995X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Acta Orthopaedica et Traumatologica Turcica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aott.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}